Cargando…

GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer

INTRODUCTION: Tamoxifen is widely used to treat hormone-dependent breast cancer, but its therapeutic benefit is limited by the development of drug resistance. Here, we investigated the role of estrogen G-protein coupled receptor 30 (GPR30) on Tamoxifen resistance in breast cancer. METHODS: Primary t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, Zhiqiang, Liu, Manran, Yang, Fangfang, Luo, Haojun, Li, Zhenhua, Tu, Gang, Yang, Guanglun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978564/ https://www.ncbi.nlm.nih.gov/pubmed/24289103 http://dx.doi.org/10.1186/bcr3581

Ejemplares similares

Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells
por: Yuan, Jie, et al.
Publicado: (2015)

GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells
por: Liu, Li, et al.
Publicado: (2021)

GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts
por: Luo, Haojun, et al.
Publicado: (2014)

Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer
por: Chen, Rui, et al.
Publicado: (2020)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells
por: Ibrahim, Amel B., et al.
Publicado: (2019)

LncRNA‐Hh Strengthen Cancer Stem Cells Generation in Twist‐Positive Breast Cancer via Activation of Hedgehog Signaling Pathway
por: Zhou, Mingli, et al.
Publicado: (2015)

MiR-205/YAP1 in Activated Fibroblasts of Breast Tumor Promotes VEGF-independent Angiogenesis through STAT3 Signaling
por: Du, Yan-e, et al.
Publicado: (2017)

Differences in GPR30 Regulation by Chlorotriazine Herbicides in Human Breast Cells
por: Florian, Colin P., et al.
Publicado: (2016)

Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing
por: Rouhimoghadam, Milad, et al.
Publicado: (2018)

Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients
por: Miranda, Carla, et al.
Publicado: (2021)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

LncGPR107 drives the self-renewal of liver tumor initiating cells and liver tumorigenesis through GPR107-dependent manner
por: Huang, Guanqun, et al.
Publicado: (2018)

In vivo Effects of a GPR30 Antagonist
por: Dennis, Megan K., et al.
Publicado: (2009)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

GPR30 mediates estrone, estriol, and estradiol to suppress gonadotropin-releasing hormone-induced luteinizing hormone secretion in the anterior pituitary of heifers
por: OTSUKA, Midori, et al.
Publicado: (2017)

Retraction Note: LncGPR107 drives the self-renewal of liver tumor initiating cells and liver tumorigenesis through GPR107-dependent manner
por: Huang, Guanqun, et al.
Publicado: (2022)

Estrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes
por: Ikeda, Yasumasa, et al.
Publicado: (2012)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

GPR54-Dependent Stimulation of Luteinizing Hormone Secretion by Neurokinin B in Prepubertal Rats
por: Grachev, Pasha, et al.
Publicado: (2012)

The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo
por: Wei, W, et al.
Publicado: (2014)

Polymorphisms of estrogen receptors, ERα and GPR30: association with breast cancer susceptibility and prognosis
por: Alves, Susana M, et al.
Publicado: (2010)

445 Inhibition of GPR30 Reveals Putative Genes Involved in the Pathogenesis of Inflammatory Breast Cancer
por: Carrion-Laureano, Melanie, et al.
Publicado: (2022)

Biological Characteristics and Genetic Heterogeneity between Carcinoma-Associated Fibroblasts and Their Paired Normal Fibroblasts in Human Breast Cancer
por: Peng, Qiongle, et al.
Publicado: (2013)

Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor α (ERα)
por: Tsai, Chia-Lung, et al.
Publicado: (2013)

Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
por: Coombes, R. C., et al.
Publicado: (1982)

Relation of hormones in ductal lavage fluid to age, tamoxifen treatment, and breast cancer risk
por: Chatterton, RT, et al.
Publicado: (2009)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

The Cell Surface Estrogen Receptor, G Protein- Coupled Receptor 30 (GPR30), is Markedly Down Regulated During Breast Tumorigenesis
por: Poola, Indira, et al.
Publicado: (2008)

Cytoplasmic kinases downstream of GPR30 suppress gonadotropin-releasing hormone (GnRH)-induced luteinizing hormone secretion from bovine anterior pituitary cells
por: RUDOLF, Faidiban O., et al.
Publicado: (2015)

G-Protein Coupled Receptor 30 (GPR30): A Novel Regulator of Endothelial Inflammation
por: Chakrabarti, Subhadeep, et al.
Publicado: (2012)

GPR30 regulates diet-induced adiposity in female mice and adipogenesis in vitro
por: Wang, Aihua, et al.
Publicado: (2016)

Low concentration of BPA induces mice spermatocytes apoptosis via GPR30
por: Wang, Chaoliang, et al.
Publicado: (2017)

Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer
por: Zhu, Cai-xia, et al.
Publicado: (2017)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Tamoxifen Initiation After Ductal Carcinoma In Situ
por: Nichols, Hazel B., et al.
Publicado: (2016)

Deficiency of Gpr1 improves steroid hormone abnormality in hyperandrogenized mice
por: Yang, Ya-Li, et al.
Publicado: (2018)

PJA1 mediates the effects of astrocytic GPR30 on learning and memory in female mice
por: Wang, Xinshang, et al.
Publicado: (2023)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_oi19lcbc2qcvhdqiv1fpemkp8b